High recurrence (50-80%) from non-muscle-invasive bladder cancer (NMIBC, 75% of all bladder cancer cases) requires invasive surveillance exams every 3 to 6 months. The exam, cystoscopy, consists of inserting a physical probe into the bladder through the urethra so that urologists can inspect for lesions, resulting in high lifetime costs, low patient compliance, and complications from trauma to the urethra (i.e: UTIs)

Cellens introduces a high accuracy urine-based test that would reduce the frequency of invasive procedures like cystoscopy needed to monitor bladder cancer and aims to set a new standard in bladder cancer diagnostics.